Sociodemographic and clinical factors associated with receipt of biomarker testing in patients with metastatic colorectal cancer.

Considerable variations exist in somatic biomarker testing across subgroups of the population. Identification of genomic alterations can aid in determining targeted treatment and improving clinical outcomes; therefore, equitable use of these testing strategies, particularly NGS, is necessary.